Abstract
The rabbit corneal micropocket assay uses the avascular cornea as a substrate to study angiogenesis in vivo. The continuous monitoring of neovascular growth in the same animal allows for the evaluation of drugs acting as suppressors or stimulators of angiogenesis. Through the use of standardized slow-release pellets, a predictable angiogenic response can be quantified over the course of 1–2 weeks. Uniform slow-release pellets are prepared by mixing purified angiogenic growth factors such as basic fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF) and a synthetic polymer to allow for their slow release. A micropocket is surgically created in the cornea thickness under anesthesia and in sterile conditions. The angiogenesis stimulus (growth factor but also tissue fragment or cell suspension) is placed into the pocket in order to induce vascular outgrowth from the limbal capillaries where vessels are preexisting. On the following days, the neovascular development and progression are measured and qualified using a slit lamp, as well as the concomitant vascular phenotype or inflammatory features. The results of the assay allow to assess the ability of potential therapeutic molecules to modulate angiogenesis in vivo, both when released locally or given by ocular formulations or through systemic treatment. In this chapter the experimental details of the avascular rabbit cornea assay, the technical challenges, advantages, and limitations are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jain RK, Schlenger K, Hockel M et al (1997) Quantitative angiogenesis assays: progress and problems. Nat Med 3:1203–1208
Nowak-Sliwinska P, Alitalo K, Allen E et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21(3):425–532. https://doi.org/10.1007/s10456-018-9613-x
Chang JH, Gabison EE, Kato T et al (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249
Ellenberg D, Azar DT, Hallak JA et al (2010) Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 29(3):208–248
Maddula S, Davis DK, Maddula S et al (2011) Horizons in therapy for corneal angiogenesis. Ophthalmology 118:591–599
Ambati BK, Nozaki M, Singh N et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993–997
Gimbrone M Jr, Cotran R, Leapman SB et al (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52:413–427
Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 363:797–800
Brem SS, Gullino PM, Medina D (1977) Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195(4281):880–882
Cervenak L, Morbidelli L, Donati D et al (2000) Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by Interleukin-10. Blood 96:2568–2573
Woolard J, Wang WY, Bevan HS et al (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64(21):7822–7835
Marconcini L, Marchio S, Morbidelli L et al (1999) c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A 96(17):9671–9676
Brem H, Folkman J (1975) Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141(2):427–439
Bard RH, Mydlo JH, Freed SZ (1986) Detection of tumor angiogenesis factor in adenocarcinoma of kidney. Urology 27(5):447–450
Gallo O, Masini E, Morbidelli L et al (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587–596
da Silva BB, da Silva Júnior RG, Borges US et al (2005) Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J Surg Oncol 90(2):77–80
Ziche M, Morbidelli L, Choudhuri R et al (1997) Nitric oxide-synthase lies downstream of vascular endothelial growth factor but not basic fibroblast growth factor induced angiogenesis. J Clin Invest 99:2625–2634
Lasagna N, Fantappiè O, Solazzo M et al (2006) Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 66(5):2673–2682
Ziche M, Morbidelli L, Masini E et al (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036–2044
Monti M, Donnini S, Morbidelli L et al (2013) PKCε activation promotes FGF-2 exocytosis and induces endothelial cell proliferation and sprouting. J Mol Cell Cardiol 63:107–117
Carriero MV, Bifulco K, Minopoli M et al (2014) UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency. Mol Cancer Ther 13(5):1092–1104. https://doi.org/10.1158/1535-7163.MCT-13-0949
Presta M, Rusnati M, Belleri M et al (1999) Purine analog 6-methylmercaptopurine ribose inhibits early and late phases of the angiogenesis process. Cancer Res 59(10):2417–2424
Ziche M, Morbidelli L (2009) Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw 20(4):164–170
Chang LK, Garcia-Cardena G, Farnebo F et al (2004) Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 101(32):11658–11663. https://doi.org/10.1073/pnas.0404272101
Taraboletti G, Morbidelli L, Donnini S et al (2000) The heparin binding 25kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinases and TIMP-2 in endothelial cells. FASEB J 14:1674–1676
Ziche M, Jones J, Gullino PM (1982) Role of prostaglandinE1 and copper in angiogenesis. J Natl Cancer Inst 69:475–482
Parenti A, Morbidelli L, Ledda F et al (2001) The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15(8):1487–1489
Federman JL, Brown GC, Felberg NT et al (1980) Experimental ocular angiogenesis. Am J Ophthalmol 89(2):231–237
Rogers MS, Birsner AE, D'Amato RJ (2007) The mouse cornea micropocket angiogenesis assay. Nat Protoc 2(10):2545–2550
Ziche M, Alessandri G, Gullino PM (1989) Gangliosides promote the angiogenic response. Lab Investig 61:629–634
Morbidelli L, Donnini S, Chillemi F et al (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 9(14):5358–5369
Bagli E, Stefaniotou M, Morbidelli L et al (2004) Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64(21):7936–7946
Donnini S, Finetti F, Lusini L et al (2006) Divergent effects of quercetin conjugates on angiogenesis. Br J Nutr 95(5):1016–1023
Cantara S, Donnini S, Morbidelli L et al (2004) Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. FASEB J 18(15):1943–1945
Acknowledgments
The work was supported by the Italian Ministry of University (MIUR) and the Italian Association for Cancer Research (AIRC). We thank Dr. Dario Rusciano, Sooft Italia SpA, for providing UPARANT.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Morbidelli, L., Ciccone, V., Ziche, M. (2021). Studying Angiogenesis in the Rabbit Corneal Pocket Assay. In: Ribatti, D. (eds) Vascular Morphogenesis. Methods in Molecular Biology, vol 2206. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0916-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0916-3_8
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0915-6
Online ISBN: 978-1-0716-0916-3
eBook Packages: Springer Protocols